At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 270 enrolled
Drug / intervention
1% OPA-15406 Ointment +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multinational, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Demonstrate the Superiority of 1% OPA-15406 Ointment to the Vehicle in Adult Patients With Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating 1% OPA-15406 Ointment and 0% OPA-15406 Vehicle for Atopic Dermatitis (AD). Completed, enrolled 270 participants across 1 site.
Detailed Summary
This is a multinational (China and Korea), multicenter, randomized, double-blind, vehicle-controlled, parallel-group, comparison trial to demonstrate the superiority of 1% OPA-15406 ointment to the vehicle in adult AD subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis (AD)
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
First PostedDec 2022
Enrollment StartFeb 2023
Primary CompletionJun 2024
Study CompletionNov 2024
TodayJul 2026
First PostedDec 28, 2022
Enrollment StartFeb 6, 2023
Primary CompletionJun 17, 2024
Study CompletionNov 29, 2024
TodayJul 1, 2026
Enrollment to primary: 1.4 yearsPosted 3.5 years ago
Interventions
1% OPA-15406 Ointmentdrug
Twice-daily administration for 4 weeks/24 weeks.
0% OPA-15406 Vehicleother
Twice-daily administration for 4 weeks/24 weeks.